A Duke University spinoff has reached a milestone in tissue engineering as it transplanted the first bioengineered blood vessel into the arm of a patient with end-stage kidney disease.
In its first U.S. clinical trial, Humacyte is testing the safety and effectiveness of the blood vessel, which is intended to be an off-the-shelf product that’s derived from human cells but doesn’t have any of the biological properties that cause organ rejection.
People with kidney disease undergo dialysis, which often requires use of a graft to connect an artery to a vein. Current options carry risks of complications, according to Duke, like clotting and infection.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Humacyte creates its vessels by cultivating donated human cells on a tubular scaffold. The resulting vessel is then cleansed of the qualities that might trigger an immune response, leaving a collagen structure that mechanically matches artery and vein it’s being sewn to.
To read more from Duke, click here.
[Photo credit: Duke University]
